New Psychiatric Provider Answering Service

AlertMD On-Call number for Psychiatry: 815-206-3437

Effective Wednesday, September 13, 2017

Situation

There is no single point of access to contact the scheduled on-call Psychiatric Provider. At times, there is confusion around who is on-call for which service, which results in delayed responses.

Background

The Psychiatric Provider team manages multiple call lists for the ED, med floors, and inpatient behavioral health unit. Schedules are distributed across departments but become quickly outdated as schedules change.

Assessment

A single point of access is required to ensure a caller can access the correct Psychiatric

Provider within a timely fashion.

Recommendation

Utilize the Center and AlertMD to establish a single access point; populating the schedule behind the scenes to ensure each caller is accessing the most up to date on-call schedule and Provider resource.

Medical Providers, Nurses, and Care Coordinators serving patients on the Medical floors will be able to access the Psychiatric Provider by calling 815-206-3437.

After dialing this number, you will hear three options:

  1. If you are calling from the ER, please press 1
  2. If you are calling from a Medical Floor, please press 2
  3. If you are calling from the Inpatient Behavioral health floor, please press 3

Once you make your selection, you will be greeted by the operator. The operator will page the psychiatrist on call through Alert MD. The Psychiatrist has 15 minutes to respond. If they do not respond, the operator will page again.

Please contact Susan Yerkes with any issues. (815)334-5582 or Email: syerkes@centegra.com

     

CT Scan Ordering Guide Added

The new CT scan ordering guide has been added here. It can be directly viewed under Clinical -> Radiology.

CHM Receives Blue Distinction Award

From: Heidi Close, Director of Women’s Services Centegra Health System

Rachel Sebastian, President McHenry Hospital

Peggy Norton-Rosko, MSN, RN, NEA-C SVP & Chief Nursing Officer Centegra Health System __________________________________________________________________________________________

We are excited to announce that Blue Cross and Blue Shield of Illinois recently awarded Centegra McHenry Hospital the Blue Distinction® Center for Maternity Care designation (BDC). Blue Distinction® is a national designation program recognizing healthcare facilities that demonstrate expertise in delivering quality specialty care – safely, effectively, and cost efficiently.

Facilities are evaluated on quality metrics developed through a process that includes:

  • Input from the medical community and quality measurement experts.
  • Review of medical literature together with national quality and safety initiatives.
  • Thorough analysis of meaningful quality measures from objective, publicly available sources.

    In addition hospitals that receive the BDC Maternity Care designation must also attest to having certain structural components in place and commit to ongoing reporting and quality improvement obligations. The program also evaluates hospitals on overall patient satisfaction, including a willingness to recommend the hospital to others. Blue Distinction® Centers demonstrate better overall patient satisfaction and a lower percentage of early elective deliveries.

    Join us in congratulating our entire Women’s Health team as they continue to provide outstanding care to our community.

Current list of Paragon ordersets

Current list of Paragon order sets are available here

Rounding Report Updates

Paragon rounding reports have been updated with:

  1. Header contains the hospital location
  2. Bed numbers sort in ascending order
  3. Footer contains the username along with date and time printed

Adding PCLS tab to flowsheets

PCLS notes can be accessed through the PCLS flowsheet

To add the PCLS (Psychiatry Consultation Liaison Service )flowsheet to the set of flowsheet tabs. First click "More flowsheets"

Open flowsheets list

Click on "manage favorites"

Add PCLS flowsheet to your list

Drag PCLS to the right column

Sort order of tabs

Order of tabs can be sorted by dragging up or down

Confirm to close selection

Click confirm to close the selection

The tab will now appear in the flowsheets

How to enter a PRN order

Edit the full order

Add PRN to an order

1. Type a dash – in the PRN box to see the whole list of options

2. Click the right arrow to activate the list

Select the parameter

Submit the order

Click the submit button

D5W / 0.45% NS Shortage 9.1.17

To:      Company-Wide

From: Dima Awad, PharmD, MS, System Director of Pharmacy Services

Date:  August 31, 2017

Re:      D5W/0.45% NS Shortage

SITUATION

We are experiencing a shortage in D5W/0.45% NS.

BACKGROUND

Medications including IV fluid shortages keep occurring at great frequency, this situation has been worsening over the past several years due to multiple factors such as fewer suppliers, inability to acquire active ingredients, issues with packaging and more.

ASSESSMENT

Currently, Pharmacy services has a 1 day supply of D5W/0.45% NS. When the current supply of D5W/0.45% NS becomes depleted, a plan for automatic substitution needs to be implemented. This is not a new workflow nor is it a change in practice in case of shortages.

RECOMMENDATION

When supply becomes depleted, Pharmacy services will initiate substitution with D5W/0.225% NS, to be administered at same infusion rate that was ordered. Pharmacy services will place “Substituted for D5W/0.45% NS” in the comment section of the Paragon order so that nursing is aware of the change. This substitution has been approved by The Pharmacy and Therapeutics Committee. Pharmacy will also maintain vigil on availability of D5W/0.225%, as we anticipate that increased use will decrease supply.

 

pembrolizumab (KEYTRUDA) in Patients with Multiple Myeloma: FDA Statement – Two Clinical Trials On Hold

Keytruda (pembrolizumab) in Patients with Multiple Myeloma: FDA Statement – Two Clinical Trials on Hold
AUDIENCE: Oncology
ISSUE: Based on data from two recently halted clinical trials, the U.S. Food and Drug Administration today is issuing this statement to inform the public, health care professionals, and oncology clinical investigators about the risks associated with the use of Keytruda (pembrolizumab) in combination with dexamethasone and an immunomodulatory agent (lenalidomide or pomalidomide) for the treatment of patients with multiple myeloma. Keytruda (pembrolizumab) is not approved for treatment of multiple myeloma.
The FDA statement is based on review of data from two clinical trials (KEYNOTE-183 and KEYNOTE-185) evaluating the use of Keytruda (pembrolizumab) combined with other treatments in patients with multiple myeloma. On July 3, 2017, the FDA required that all patients in these trials be discontinued from further investigation with this drug, because interim results from both trials demonstrated an increased risk of death for patients receiving Keytruda (pembrolizumab) when it was combined with an immunomodulatory agent as compared to the control group (see statistical analysis section below). Merck & Co., Inc. was made aware of the issue through an external data monitoring committee recommendation and suspended the trials to enrollment on June 12, 2017. Continue reading